Investigational Digestive & weight

Amycretin

Amycretin is an amylin + GLP-1 co-agonist. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it is being studied in clinical trials and is not approved by the FDA.

Regulatory status

Amycretin is investigational.

It has not been approved by the FDA for any use.

ClinicalTrials.gov lists 1 registered study for it.

The evidence

What has actually been published

3 sources on Amycretin published between 2025 and 2026, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on digestive & weight

Start with your own numbers.

Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.

See the OPTML Score

Educational reference only. This page explains what has been published about Amycretin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides